Emerging drug delivery systems to alter tumor immunosuppressive microenvironment: Overcoming the challenges in immunotherapy for glioblastoma.

3区 生物学 Q2 Biochemistry, Genetics and Molecular Biology
P Soma Yasaswi, Harsh P Nijhawan, Bala Prabhakar, Shilpee Dutt, Khushwant S Yadav
{"title":"Emerging drug delivery systems to alter tumor immunosuppressive microenvironment: Overcoming the challenges in immunotherapy for glioblastoma.","authors":"P Soma Yasaswi, Harsh P Nijhawan, Bala Prabhakar, Shilpee Dutt, Khushwant S Yadav","doi":"10.1016/bs.pmbts.2024.04.006","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma (GBM) is a highly proliferative, lethal cancer of the brain. The median survival at eight months is ca. 6.8%. Resistance towards the anti-glioblastoma drug temozolomide (TMZ), recurrence of cancer cells, blood-tumor brain barrier (BTBB), blood-brain barrier (BBB), and tumor immunosuppression are major challenges in treating GBM. Drug delivery systems employing TMZ and other anti-cancer drugs and combination therapy (temozolomide with immunotherapeutics) are under pre-clinical and clinical studies, respectively. Immunotherapeutics have emerged as a dominant mechanism to silence tumor development and dissemination. Paradoxically, immunotherapy has witnessed failure in treating GBM. This is due to the unique immunosuppressive microenvironment in GBM. Future immunotherapeutics with inherent tumor environment-modulating properties have to be identified. In this review, we discuss recent delivery systems and devices engineered to deliver immunotherapeutics with the ability to alter/silence tumor immune suppression.</p>","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"209 ","pages":"165-182"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in molecular biology and translational science","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/bs.pmbts.2024.04.006","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Glioblastoma (GBM) is a highly proliferative, lethal cancer of the brain. The median survival at eight months is ca. 6.8%. Resistance towards the anti-glioblastoma drug temozolomide (TMZ), recurrence of cancer cells, blood-tumor brain barrier (BTBB), blood-brain barrier (BBB), and tumor immunosuppression are major challenges in treating GBM. Drug delivery systems employing TMZ and other anti-cancer drugs and combination therapy (temozolomide with immunotherapeutics) are under pre-clinical and clinical studies, respectively. Immunotherapeutics have emerged as a dominant mechanism to silence tumor development and dissemination. Paradoxically, immunotherapy has witnessed failure in treating GBM. This is due to the unique immunosuppressive microenvironment in GBM. Future immunotherapeutics with inherent tumor environment-modulating properties have to be identified. In this review, we discuss recent delivery systems and devices engineered to deliver immunotherapeutics with the ability to alter/silence tumor immune suppression.

改变肿瘤免疫抑制微环境的新兴给药系统:克服胶质母细胞瘤免疫疗法的挑战。
胶质母细胞瘤(GBM)是一种高度增殖的致命脑癌。八个月的中位生存率约为 6.8%。抗胶质母细胞瘤药物替莫唑胺(TMZ)的抗药性、癌细胞复发、血瘤脑屏障(BTBB)、血脑屏障(BBB)和肿瘤免疫抑制是治疗胶质母细胞瘤的主要挑战。采用替莫唑胺和其他抗癌药物的给药系统以及联合疗法(替莫唑胺与免疫疗法)正在分别进行临床前和临床研究。免疫疗法已成为抑制肿瘤发展和扩散的主要机制。但令人不解的是,免疫疗法在治疗 GBM 方面却以失败告终。这是由于 GBM 独特的免疫抑制微环境造成的。未来必须找到具有内在肿瘤环境调节特性的免疫疗法。在这篇综述中,我们将讨论最近设计用于递送免疫治疗药物的递送系统和设备,它们具有改变/抑制肿瘤免疫的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Progress in Molecular Biology and Translational Science (PMBTS) provides in-depth reviews on topics of exceptional scientific importance. If today you read an Article or Letter in Nature or a Research Article or Report in Science reporting findings of exceptional importance, you likely will find comprehensive coverage of that research area in a future PMBTS volume.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信